Angela Styhler
Hôpital Maisonneuve-Rosemont(CA)
Publications by Year
Research Areas
Phosphodiesterase function and regulation, Cholinesterase and Neurodegenerative Diseases, Receptor Mechanisms and Signaling, Asthma and respiratory diseases, Inflammatory mediators and NSAID effects
Most-Cited Works
- → Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia(2011)141 cited
- → Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor(2004)101 cited
- → The Discovery of Setileuton, a Potent and Selective 5-Lipoxygenase Inhibitor(2010)79 cited
- → The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor‐α and leukotriene B4 in a novel human whole blood assay(1999)69 cited
- → Optimization of a Tertiary Alcohol Series of Phosphodiesterase-4 (PDE4) Inhibitors: Structure−Activity Relationship Related to PDE4 Inhibition and Human Ether-a-go-go Related Gene Potassium Channel Binding Affinity(2003)66 cited
- → In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)(2001)46 cited
- → Synthesis of 5-oxo-6,8, 11, 14-eicosatetraenoic acid by human monocytes and lymphocytes(1996)44 cited
- → Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment(2010)43 cited
- → Antiproliferative effect of prostaglandin E2 in cultured guinea pig tracheal smooth muscle cells(1994)37 cited
- → Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: Structure–activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor(2005)30 cited